Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. (noting a discrepancy with the metadata name "Bio Green Med Solution, Inc.") on September 12, 2012. The report addresses a material modification to the rights of security holders regarding the company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The primary financial disclosure relates to the non-payment of dividends on the Preferred Stock.
Material Changes
- Dividend Omission: The Board of Directors decided not to declare the quarterly cash dividend for the third quarter of 2012, which was scheduled to be payable on November 1, 2012.
- Accumulated Arrears: This omission adds to a history of unpaid dividends, including all four quarters of fiscal year 2009, the first three quarters of fiscal year 2010, the last three quarters of fiscal year 2011, and the first three quarters of fiscal year 2012.
- Board Composition Change: Due to the failure to pay an aggregate of at least six quarterly dividends, the Board size was increased by two members. Holders of the Preferred Stock elected two directors on May 24, 2011, to fill these vacancies.
Outlook, Risks, and Contingencies
Contingency on Directorships: The two directorships held by Preferred Stock holders will terminate only when the Company pays all accrued but unpaid dividends. Until such payment is made, the Preferred Stock holders retain the right to elect these directors.
Accrual of Dividends: Unpaid dividends are accrued, increasing the company's liability to Preferred Stock holders over time.
Investor Verification Checklist
- Verify the total amount of accrued but unpaid dividends on the 6% Convertible Exchangeable Preferred Stock.
- Confirm the current composition of the Board of Directors and the specific identities of the directors elected by Preferred Stock holders.
- Review the company's cash position and liquidity to assess the feasibility of paying accrued dividends in the near term.
- Check for any subsequent filings regarding the declaration of dividends or changes in the Board structure.